SANIONA IT S.R.L.

Rare diseases are, by definition, rare. But their impact on those affected is anything but marginal: diagnostic journeys that often last years, absent or inadequate therapies, and small scattered patient communities that rarely manage to attract the attention and investment of the mainstream pharmaceutical industry. SANIONA IT S.R.L., the Italian arm of the Saniona group, operates in this space with a precise mission: improving the lives of rare disease patients worldwide through scientific innovation. Saniona is a life sciences company focused on developing therapies for conditions with unmet medical needs — primarily rare, neurological, and metabolic diseases. Its research pipeline is built around innovative therapeutic candidates that aim to fill the gaps left open by mainstream industry, which frequently avoids therapeutic niches where the potential market is limited and clinical development is complex. Saniona's main partners are pharmaceutical companies interested in therapies for high-need niches, life science investors, and the clinical communities working on these conditions. The B2B model includes licensing agreements, development partnerships, and collaborations with specialized research centers. At a time when rare disease research is attracting growing attention from both European regulators and investors — driven in part by advances in genomics and precision medicine — Saniona positions itself as a scientifically rigorous actor with a clear ethical focus and an actively developing portfolio.